BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Trial details
- Registry ID
- NCT04819373
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsNCT04819373 | Eikon Therapeutics | Phase 2 | Completed | 2023-04-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |